Phase 2 Study on the Pharmacokinetics and Safety of RLYB212 in Pregnant Women at Higher Risk for HPA-1a Alloimmunization

Stopped This study was terminated early by the sponsor due to insufficient drug exposure to achieve the intended therapeutic effect.

Conditions

• Fetal and Neonatal Alloimmune Thrombocytopenia

Interventions

• DRUG: Anti-(integrin beta-3) human monoclonal antibody

Sponsor

Rallybio